Mumbai, June 24 -- The said contracts have been awarded to Duopharma (M) Sendirian Berhad, a wholly-owned subsidiary of Duopharma Biotech.

As part of these contracts, Biocon's subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution.

The contracts comprise a three-year agreement valued at MYR 155.27 million for human insulin, along with two two-year agreements, which consists of MYR 18 million contract for insulin glargine and MYR 52.5 million contract for insulin aspart.

Shreehas Tambe, CEO & managing director, Biocon, said: "Malaysia has been central to Biocon's insulin journey for over a decade, anchored by our i...